Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
52.9 PLN | -0.19% | -3.11% | -8.00% |
Business Summary
Sales per Business
PLN in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Small Molecule Therapies
100.0
%
| 39 | 100.0 % | 47 | 100.0 % | +20.32% |
Sales per region
PLN in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
European Union Countries
88.9
%
| 25 | 63.2 % | 42 | 88.9 % | +69.25% |
Other Countries
11.0
%
| 14 | 36.5 % | 5 | 11.0 % | -63.73% |
Poland
0.1
%
| 0 | 0.3 % | 0 | 0.1 % | -64.15% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 06-12-31 | |
Hendrik Nogai
CTO | Chief Tech/Sci/R&D Officer | - | 22-01-31 |
Chief Operating Officer | 38 | 12-12-31 | |
Chief Tech/Sci/R&D Officer | - | 06-12-31 | |
Vatnak Vat-Ho
PRN | Corporate Officer/Principal | - | 21-04-25 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | - | |
Scott Fields
BRD | Director/Board Member | 69 | 23-06-13 |
Thomas Turalski
BRD | Director/Board Member | - | - |
Rafal Chwast
BRD | Director/Board Member | - | - |
Piotr Romanowski
CHM | Chairman | - | 18-12-31 |
Director/Board Member | 64 | 19-09-30 | |
Peter Smith
BRD | Director/Board Member | - | 23-06-13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 23,120,148 | 14,971,356 ( 64.75 %) | 8 ( 0.000035 %) | 64.75 % |
Company contact information
Sector
Sales per region
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.00% | 302M | |
-3.10% | 102B | |
+2.11% | 96.37B | |
-1.80% | 21.37B | |
-17.75% | 20.92B | |
-6.91% | 18.64B | |
-42.00% | 16.4B | |
-28.19% | 13.53B | |
+0.18% | 13.28B | |
+19.90% | 10.85B |
- Stock Market
- Equities
- RVU Stock
- Company Ryvu Therapeutics S.A.